Corrao, Madeline M.
Nelson, Leigh Anne http://orcid.org/0000-0003-1481-8682
Article History
Accepted: 13 April 2022
First Online: 30 May 2022
Declarations
:
: The authors received no financial support for the research, authorship, and/or publication of this article.
: The authors declaration of conflict of interest is as follows: Madeline M. Corrao has nothing to disclose. Leigh Anne Nelson served on an advisory board for Sunovion and Janssen pharmaceutical companies. She has received research funding from Boehringer Ingelheim, Alkermes, Inc. She is also a consultant in the speaker’s bureau of Alkermes Inc. for the following drugs: Aristada and Lybalvi. Alkermes, Inc. is the manufacturer of Lybalvi (olanzapine/samidorphan).
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Madeline M. Corrao conducted a literature analysis, wrote the paper, and completed revisions. Leigh Anne Nelson conceived the paper concept, conducted a literature analysis, edited the paper, submitted the paper, and is solely responsible for completing the revisions following peer review.